MiNK Therapeutics, Inc. (INKT) News
Track canonical SquawkNews coverage tagged to INKT, MiNK Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 6 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
MiNK Therapeutics (INKT) Selected for ARPA-H BoSS Initiative
MiNK Therapeutics was selected as a therapeutic cell platform for an ARPA-H BoSS team aiming to enable room—temperature cell therapy storage; ARPA-H has committed up to $87M across the four-year program.Material DetailsC
NEWS | Sep 30, 2026, 12:01 PM UTC
L
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
Clinical-stage agenT-797 iNKT platform selected as therapeutic cell platform for ARPA-H BoSS program aimed at taking living medicines from cryogenic storage toward room temperatureARPA-H has committed up to $87 million a
NEWS | Sep 30, 2026, 12:01 PM UTC
L
MiNK Therapeutics opens randomized phase 2 Agent 797 study
MiNK Therapeutics says it moved Agent 797 into a randomized phase 2 study for acute lung injury and ARDS and reported narrowed net loss of $3.1 million with cash and equivalents of $8.8 million.
EARNINGS | Aug 13, 2026, 01:29 PM UTC
L
MiNK Therapeutics (INKT) reports Q2 2026 results; Phase 2 agenT-797 observations
MiNK Therapeutics (INKT) reports second-quarter 2026 financial results and observations from a randomized Phase 2 trial of agenT-797 in acute lung injury.
EARNINGS | Aug 13, 2026, 11:30 AM UTC
M
MiNK Therapeutics Presents Phase 2 Trial Observations
MiNK Therapeutics shares early Phase 2 trial results
EQUITY | Aug 06, 2026, 04:00 PM UTC
L
INKT - MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highligh
INKT - MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
EARNINGS | Aug 06, 2026, 12:19 PM UTC